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Chk1 inhibitors potentiated the apoptosis-inducing effects of irinotecan 

































Chk1 inhibitors abrogated cell-cycle arrest and enhanced DNA-damaging 

































Functional integrity of p53 pathway in HIM models. Mice harboring 
WU-BC3, WU-BC4, and WU-BC5 were treated with vehicle (V) or iri-
notecan (I), and tumors were isolated 24 hours later. Lysates were 
prepared and resolved by SDS-PAGE and analyzed for the indicated 
proteins by Western blotting. Note the increased baseline p53 expres-
sion due to the missense mutation in WU-BC4 (lane 3) compared with 
WU-BC3 (lane 1) and the absence of intact p53 protein due to the 
deletion mutation in WU-BC5 (lane 5).
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Chk1 inhibitors in combination with irinotecan improved host sur-















Identification of the PAM50 intrinsic 
subtypes in the WU-BC models. 
Hierarchical clustering of different 
passages of WU-BC3, WU-BC4, 
and WU-BC5, their human counter-
parts (for WU-BC4 and WU-BC5), 
an ovarian metastasis from a 
mouse harboring WU-BC5, and 
40 breast samples representing 
all breast tumor subtypes, includ-
ing the normal breast–like group 
(i.e., prototypic tumor samples), 
were analyzed. Black squares 
represent samples from the xeno-
grafts. White squares represent 
human specimens. Expression of 
the PAM50 genes was centered 
on the prototypic tumor samples. 
Columns, samples; rows, genes; 
red and green squares denote 
expression levels above or below 
the median, respectively. The 
magnitude of deviation from the 
median is represented by color 
saturation. The array and gene 
trees represent overall similarities 
in gene expression.
Table 1
Experimental therapy for biomarker studies
	 	 	 Treatment	group	
Time	point	 Vehicle	 Irinotecan	 UCN-01	or	AZD7762	 Irinotecan	+	UCN-01	or	Irinotecan	+	AZD7762
0 Vehicle 100 mg/kg Vehicle Irinotecan 100 mg/kg
24 hours Vehicle Harvest tumor UCN-01 4 mg/kg or AZD7762 25 mg/kg UCN-01 4 mg/kg or AZD7762 25 mg/kg
42 hours Vehicle  UCN-01 4 mg/kg or AZD7762 25 mg/kg UCN-01 4 mg/kg or AZD7762 25 mg/kg
48 hours Harvest tumor Harvest tumor Harvest tumor Harvest tumor
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Chk1 inhibitors potentiate irinotecan-induced apoptosis selectively in TP53 mutant tumors. Mice harboring WU-BC3, WU-BC4 or WU-BC5 
TNBC were treated as indicated, and tumors were analyzed for cleaved caspase-3 by IF staining (A and B) or IHC staining (D). Representative 
images are shown in A, B, and D, with quantitations ± 95% CIs shown in C (for data in A and B) and E (for data in D), respectively. Original 
magnification, ×400. See Methods for experimental details. Statistics were obtained by the Wilson score method in SPSS 20. Notable com-
parisons are marked with ***P < 0.001.
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Knockdown of p53 sensitizes WU-BC3 tumors to combination therapy. 
Although TP53 can be sequenced in each HIM line and the func-



























Chk1 inhibitors enhance DNA damage and abrogate cell-cycle arrest induced by irinotecan selectively in p53 mutant tumors. Mice harboring 
WU-BC3 and WU-BC4 TNBC were treated as indicated, and tumors were costained for phosphohistone H3 (pH3, red) and γH2AX (green). Rep-
resentative IF images are shown in A and B, and quantitation ± 95% CIs are shown in C–E. Statistics were obtained by the Wilson score method 
in SPSS 20. **P < 0.01; ***P < 0.001. Original magnification, ×400. (F) Mice harboring WU-BC3 or WU-BC4 tumors were treated as indicated; 
tumors were lysed and analyzed by Western blotting with antibodies specific for S6 ribosomal protein, phosphorylated S6 ribosomal protein (pS6), 
and actin as a loading control. The ratio of phosphorylated S6 to total S6 protein was determined for each sample. Blots were developed using ECL 
detection reagent (GE Healthcare), and proteins were quantitated using ImageJ (53). Mean ratios are shown with 95% CIs. *P < 0.05.
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Enhanced DNA damage and checkpoint bypass in p53-deficient TNBC treated with combination therapy. Mice harboring WU-BC3 and WU-BC5 
TNBC were treated as indicated, and tumors were stained for γH2AX (A) and phosphohistone H3 (C). Original magnification, ×400 (A); ×200 (C). 
Representative IHC images are shown in A and C; quantitation ± 95% CIs are shown in B and D. Statistics were obtained by the Wilson score 
method in SPSS 20. ***P < 0.001.
research article
	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 122      Number 4      April 2012  1547
Discussion
Using HIM tumor models of TNBC, we demonstrated that UCN-01 





















































Effect of combination therapy on tumor growth and host survival. Tumor-bearing NOD/SCID mice were randomly assigned to the indicated treat-
ment groups (vehicle, irinotecan, AZD7762, or the combination of irinotecan and AZD7762; n = 10 per group). Mice were followed until death or 
sacrificed if tumor size reached 2 cm or mice experienced unacceptable toxicities. (A) Kaplan-Meier survival curve following therapy initiation 
using animal sacrifice as the terminal event. Animals dying of other causes were right-censored from the analysis at the observed time of death 
and are marked on the survival curves with an X. (B) Median time to animal sacrifice for mice treated in each treatment arm. (C and D) Tumor 
growth following therapy initiation for individual mice in each treatment group for WU-BC3 and WU-BC4, respectively. (E) Tumor growth curve 
for individual mice treated with either irinotecan or the combination of irinotecan and AZD7762.
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p53 status is a key determinant of how TNBCs respond to DNA damage followed by Chk1 inhibition. WU-BC3 cells were infected with control 
retroviruses or retroviruses encoding p53-specific shRNAs to generate the BC3-p53WT and BC3-p53KD lines, respectively. (A and B) Cells were 
either mock irradiated (–) or exposed to 10 Gy IR (+) and then monitored for the integrity of the p53 pathway by observing changes in the levels of 
p53 and p21 by Western blotting (A) and for the integrity of HRR by monitoring for the appearance of Rad51 foci (B; pink stain, Rad 51). Original 
magnification, ×400. (C) Timeline of treatment of cells with either vehicle, irinotecan, AZD7762, the Chk2 inhibitor, or irinotecan in combination 
with AZD7762 or the Chk2 inhibitor. Cell lysates were prepared and analyzed for the indicated proteins by Western blotting (D).
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Figure 8
p53 status is the key determinant of TNBC response to DNA damage followed by Chk1 inhibition in vivo. Mice harboring BC3-p53WT and BC3-
p53KD were treated as indicated, and tumors were analyzed by IF staining for cleaved caspase-3 and costaining for phosphohistone H3 or 
γH2AX. (A) Representative IF costaining for cleaved caspase-3 (green) and γH2AX (red). Quantitation is shown for cleaved caspase-3–positive 
(B), γH2AX-positive (C), and cleaved caspase-3–negative cells that are positive for γH2AX (D). (E) Representative IF costaining for pH3 (red) 
and γH2AX (green). Original magnification, ×400. Quantitation is shown in F (pH3), G (γH2AX), and H (pH3-positive cells also positive for γH2AX). 
Statistics were obtained by the Wilson score method in SPSS 20. **P < 0.01; ***P < 0.001.
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